RPTX Repare Therapeutics
- 3.150
- +0.130+4.30%
Repare Therapeutics News
Repare Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Segal Lloyd Mitchell
Repare Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Forte Steve
Repare Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Zinda Michael
Repare Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Koehler Maria
Repare Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Forte Steve
Repare Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Zinda Michael
Repare Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Koehler Maria
Repare Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Segal Lloyd Mitchell
Repare Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Repare Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Repare Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Repare Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Repare Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Repare Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Forte Steve
Repare Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Zinda Michael
Repare Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Segal Lloyd Mitchell
Repare Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Koehler Maria
Repare Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Repare Therapeutics | 10-K: Annual report
Repare Therapeutics | 8-K: Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Analysis
Price Target
No Data
